DE69329023D1 - T-peptid und damit verwandte peptide in der behandlung von entzündungen einschliesslich der multiplen sklerose - Google Patents

T-peptid und damit verwandte peptide in der behandlung von entzündungen einschliesslich der multiplen sklerose

Info

Publication number
DE69329023D1
DE69329023D1 DE69329023T DE69329023T DE69329023D1 DE 69329023 D1 DE69329023 D1 DE 69329023D1 DE 69329023 T DE69329023 T DE 69329023T DE 69329023 T DE69329023 T DE 69329023T DE 69329023 D1 DE69329023 D1 DE 69329023D1
Authority
DE
Germany
Prior art keywords
absent
thr
ser
gly
cys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69329023T
Other languages
English (en)
Other versions
DE69329023T2 (de
Inventor
Joergen Andersen
Roger Aston
Louis Carlen
Reed Doob
Kevin Macfadden
James Phipps
Deborah Rathjen
Fred Widmer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Advanced Immuni T Inc
Original Assignee
Advanced Immuni T Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DK92645A external-priority patent/DK64592D0/da
Application filed by Advanced Immuni T Inc filed Critical Advanced Immuni T Inc
Publication of DE69329023D1 publication Critical patent/DE69329023D1/de
Application granted granted Critical
Publication of DE69329023T2 publication Critical patent/DE69329023T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69329023T 1992-03-27 1993-03-29 T-peptid und damit verwandte peptide in der behandlung von entzündungen einschliesslich der multiplen sklerose Expired - Fee Related DE69329023T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US85883292A 1992-03-27 1992-03-27
DK92645A DK64592D0 (da) 1992-05-14 1992-05-14 Peptider til terapeutisk behandling
US91511892A 1992-07-17 1992-07-17
US98767492A 1992-12-09 1992-12-09
PCT/GB1993/000649 WO1993020102A1 (en) 1992-03-27 1993-03-29 Peptide t and related peptides in the treatment of inflammation, including multiple sclerosis

Publications (2)

Publication Number Publication Date
DE69329023D1 true DE69329023D1 (de) 2000-08-17
DE69329023T2 DE69329023T2 (de) 2001-03-22

Family

ID=27439352

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69333537T Expired - Fee Related DE69333537T2 (de) 1992-03-27 1993-03-29 T-peptid und damit verwandte Peptide in der Behandlung von entzündungen einschlies slich der Multiplen Sklerose
DE69329023T Expired - Fee Related DE69329023T2 (de) 1992-03-27 1993-03-29 T-peptid und damit verwandte peptide in der behandlung von entzündungen einschliesslich der multiplen sklerose

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69333537T Expired - Fee Related DE69333537T2 (de) 1992-03-27 1993-03-29 T-peptid und damit verwandte Peptide in der Behandlung von entzündungen einschlies slich der Multiplen Sklerose

Country Status (12)

Country Link
EP (2) EP0635027B1 (de)
JP (1) JP3520084B2 (de)
KR (1) KR100312300B1 (de)
AT (2) ATE194495T1 (de)
AU (3) AU684713B2 (de)
CA (1) CA2132516A1 (de)
DE (2) DE69333537T2 (de)
DK (2) DK0960886T3 (de)
ES (2) ES2222625T3 (de)
PT (1) PT960886E (de)
UA (1) UA41881C2 (de)
WO (1) WO1993020102A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739109A (en) * 1988-12-16 1998-04-14 Advanced Immunit Inc. Method of treating neuroinflammatory degenerative diseases
JP3499562B2 (ja) * 1993-09-24 2004-02-23 アドヴァンスト・イミューニット・インク Ｃｒｏｈｎ’ｓ病および／または潰瘍性大腸炎の治療もしくは予防
JP3623231B2 (ja) * 1993-09-24 2005-02-23 アドヴァンスト・イミューニット・インク 湿疹／皮膚炎の予防または治療方法
EP1242109A4 (de) * 1999-11-09 2004-06-02 Advanced Immunit Inc Verfahren zur behandlung von viuruserkrankungen und anderen störungen durch veränderung der "immediate gene expression" durch verabreichung von peptid t
JP4611233B2 (ja) * 2005-04-06 2011-01-12 ニッタ株式会社 歩行訓練支援装置
US10501494B2 (en) * 2013-04-26 2019-12-10 Creative Bio-Peptides Uses of peptides to treat brain injury and disease
EP2832373B1 (de) * 2013-08-02 2017-04-12 Experimentelle Pharmakologie & Onkologie Berlin Buch Liposom zur Blockierung eines standortspezifischen chemokinassoziierten entzündlichen Prozesses bei Gefäßerkrankungen und Metastasen

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987007614A1 (en) * 1986-06-03 1987-12-17 Pert Candace B Small peptides which inhibit binding to t-4 receptors
NZ221440A (en) * 1986-08-20 1991-11-26 Genetic Systems Corp Composition containing monoclonal antibodies/peptides useful in treating and diagnosing hiv infections
WO1988009338A1 (en) * 1987-05-22 1988-12-01 Syntbiotech, Inc. Synthetic peptides and a method of treating aids
DE68928752T2 (de) * 1988-05-27 1998-12-03 Us Health Zubereitungen zur verwendung bei der behandlung von psoriasis und von neuropsychiatrischen krankheiten
US5189022A (en) * 1988-05-27 1993-02-23 The United States Of America As Represented By The Secretary Of Health And Human Services Composition for the treatment of chronic fatigue syndrome

Also Published As

Publication number Publication date
AU2254999A (en) 1999-05-20
DK0960886T3 (da) 2004-09-27
PT960886E (pt) 2004-10-29
JPH07507061A (ja) 1995-08-03
KR100312300B1 (ko) 2002-03-20
ATE194495T1 (de) 2000-07-15
AU3895393A (en) 1993-11-08
AU6354298A (en) 1998-06-18
JP3520084B2 (ja) 2004-04-19
EP0635027A1 (de) 1995-01-25
DE69333537D1 (de) 2004-07-01
EP0960886B1 (de) 2004-05-26
KR950700931A (ko) 1995-02-20
EP0635027B1 (de) 2000-07-12
AU684713B2 (en) 1998-01-08
DE69333537T2 (de) 2005-06-16
EP0960886A1 (de) 1999-12-01
WO1993020102A1 (en) 1993-10-14
DE69329023T2 (de) 2001-03-22
CA2132516A1 (en) 1993-10-14
ES2222625T3 (es) 2005-02-01
DK0635027T3 (da) 2000-10-02
UA41881C2 (uk) 2001-10-15
ES2149203T3 (es) 2000-11-01
AU718442B2 (en) 2000-04-13
ATE267838T1 (de) 2004-06-15
AU725680B2 (en) 2000-10-19

Similar Documents

Publication Publication Date Title
DE69627704T2 (de) Protegrine
DK0711305T3 (da) Protegriner
ATE108662T1 (de) Antimikrobielle peptide, zusammensetzungen, die diese enthalten, und verwendungen daraus.
SE9100799L (sv) Rekombinant derivat av human faktor viii
DE59007517D1 (de) Neue proteine mit tnf-hemmender wirkung und ihre herstellung.
ATE171712T1 (de) Neuartiger menschlicher proteaseinhibitor vom kunitz-typ und entsprechende varianten
DE69329023D1 (de) T-peptid und damit verwandte peptide in der behandlung von entzündungen einschliesslich der multiplen sklerose
DK0573538T3 (da) Peptider til behandling
CA2006087A1 (en) Polypeptides isolated from the venom of the spider hololena curta
RU94027578A (ru) Фармацевтическая композиция и способ лечения рассеянного склероза
ATE211765T1 (de) Neue familie von proteaseinhibitoren und andere biologisch aktive substanzen
ATE3773T1 (de) An peptide polymerisationsprodukte gebundene muramyl-peptide und sie enthaltende pharmazeutische zusammensetzungen.
Carrell et al. Structural mobility of antithrombin and its modulation by heparin
ATE120758T1 (de) Peptide, deren verwendung als hemmer gegen entwicklung von t-lymphocyten und wirksamkeit von makrophagen und verfahren zu deren herstellung.
KR950702574A (ko) 펩티드 폐 계면활성제 및 치료용 혼합물(Peptide Lung Surfactants and Therapeutic Combinations)
ATE308617T1 (de) Rantes mutanten und deren therapeutischen anwendungen
RU94046096A (ru) Линейные или циклические пептиды, их применение, способы лечения и конъюгаты пептидов
DE68905097D1 (de) Peptid-molekuele, wirksam gegen gram-positive keime.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee